SPECIALTY TOPICS · GUIDE
Why Different Substances Cannot Be Treated as Equivalent
Content last updated . This page has not been medically reviewed.
Back to Psychedelic TherapyOne heading, many different substances
"Psychedelics" is often used as a single word for very different things. Sources used by this library describe different origins, different main brain systems, different documented risks and different regulatory standing. A finding about one substance, preparation or condition does not automatically apply to another.Side by side
| Substance | Group in the sources | Origin | Main action described | Notable documented point |
|---|---|---|---|---|
| Psilocybin | Classic psychedelic [1] | Certain mushrooms [2] | Mostly 5-HT2A, but at many serotonin receptors [3] | Breakthrough Therapy designation for two formulations in depression research [4] |
| Mescaline | Classic psychedelic [1] | Cacti such as peyote [6] | 5-HT2A/2C plus other receptors [6] | US federal rules exempt nondrug peyote use in bona fide Native American Church ceremonies from the Schedule I listing (21 CFR 1307.31, read 2026-10-22); laws change [7] |
| DMT | Classic psychedelic [1] | Leaves of Psychotria viridis, a plant in ayahuasca [8] | 5-HT1A/2A partial agonist [8] | Ayahuasca also contains other compounds such as beta-carbolines [8] |
| Ibogaine | "Other" group [1] | Shrub Tabernanthe iboga [11] | Variety of receptors [1] | Associated with long QT syndrome [1] |
| Salvinorin A (salvia) | "Other" group [1] | Salvia divinorum [12] | Kappa opioid receptors [1] | Mazatec use for centuries [12] |
| Muscimol and ibotenic acid | Outside the classic group; acts on GABA [13] | Amanita muscaria [14] | Potent GABA agonists [13] | Case reports of serious toxicity including a death [15] |
The table is a map, not a ranking. It says nothing about which substance is "stronger" or "better", and this library gives no comparisons of amounts or potency between substances, species or preparations. NIDA notes that amount, potency, a person's biology and the setting all influence effects. [1]
Why "interchangeable" is the wrong idea
- Different receptors. Serotonin 5-HT2A, NMDA, kappa opioid and GABA systems are all involved across this list. See Serotonin Receptors in Plain Language.
- Different evidence. FDA says psychedelic drug programs are subject to the same regulations and evidentiary standards as other drug development programs, which means each product and use must meet them on its own. [16] Not every substance has been studied for every condition. See Psychedelic Clinical Trials and Research Limits.
- Different forms. A mushroom, a cactus, a brew, a purified compound and a clinical product are not the same thing. See Traditional Preparations vs Isolated Compounds and Clinical Products.
- Different cultural meanings. Plants such as peyote and iboga belong to specific peoples and traditions. See Indigenous Traditions, Ethics and Conservation.
Look-alike pairs that are not the same
- Psilocybin and psilocin: see Psilocybin vs Psilocin.
- DMT and 5-MeO-DMT: see DMT vs 5-MeO-DMT.
- Iboga and ibogaine: see Iboga vs Ibogaine.
Evidence labels
The table is classification and documented regulatory facts, not evidence of benefit. [4] Nothing else in the table carries that label.Education only
This page compares categories. It gives no amounts, no sourcing, no combination advice and no advice to self-treat. If you take any medicine, see how interactions work.Frequently asked questions
Do all of these substances act on serotonin?
No. [1][13]
Is there a ranking of safest to riskiest?
This library does not give one. Risks depend on the substance, form, person and setting. [1]
References
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- National Institute on Drug Abuse, Psilocybin (Magic Mushrooms). Read 2026-10-22.
- Ling S et al. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs. 2022;36(1):17-30. Read 2026-10-22 (abstract on PubMed).
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs as Medicines. Read 2026-10-22.
- Vamvakopoulou IA et al. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. Read 2026-10-22 (abstract on PubMed).
- US Electronic Code of Federal Regulations, 21 CFR 1307.31 Native American Church. Read 2026-10-22.
- Dos Santos RG, Hallak JEC. Ayahuasca: pharmacology, safety, and therapeutic effects. CNS Spectr. 2024;30(1):e2. Read 2026-10-22 (abstract on PubMed).
- Litjens RP, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297-302. Read 2026-10-22 (abstract on PubMed).
- Grundmann O et al. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology. Planta Med. 2007;73(10):1039-46. Read 2026-10-22 (abstract on PubMed).
- Okhovat A et al. Psychoactive Isoxazoles, Muscimol, and Isoxazole Derivatives from the Amanita (Agaricomycetes) Species: Review of New Trends in Synthesis, Dosage, and Biological Properties. Int J Med Mushrooms. 2023;25(9):1-10. Read 2026-10-22 (abstract on PubMed).
- Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. 2003;107(Pt 2):131-46. Read 2026-10-22 (abstract on PubMed).
- Meisel EM et al. Two Cases of Severe Amanita Muscaria Poisoning Including a Fatality. Wilderness Environ Med. 2022;33(4):412-416. Read 2026-10-22 (abstract on PubMed).
- US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.